This conclusion is also supported by Liu et al. [55], who found that among nearly 500 patients with NSCLC, those harboring macrophages expressing PD-L1 had better overall survival when treated with anti-PD-1/PD-L1 therapy. Here, CD274 is linked to non-small cell lung carcinoma.